Abstract:BACKGROUND: Skeletal muscle wasting is a devastating consequence of cancer that affects up to 80% of cancer patients and associates with reduced survival. Herein, we investigated the biological significance of Forkhead box P1 (FoxP1), a transcriptional repressor that we demonstrate is up-regulated in skeletal muscle in multiple models of cancer cachexia and in cachectic cancer patients.METHODS: Inducible, skeletal muscle-specific FoxP1 over-expressing (FoxP1iSkmTg/Tg ) mice were generated through crossing conditional Foxp1a transgenic mice with HSA-MCM mice that express tamoxifen-inducible Cre recombinase under control of the skeletal muscle actin promoter. To determine the requirement of FoxP1 for cancer-induced skeletal muscle wasting, FoxP1-shRNA was packaged and targeted to muscles using AAV9 delivery prior to inoculation of mice with Colon-26 Adenocarcinoma (C26) cells.RESULTS: Up-regulation of FoxP1 in adult skeletal muscle was sufficient to induce features of cachexia, including 15% reduction in body mass (P < 0.05), and a 16-27% reduction in skeletal muscle mass (P < 0.05) that was characterized by a 20% reduction in muscle fibre cross-sectional area of type IIX/B muscle fibres (P = 0.020). Skeletal muscles from FoxP1iSkmTg/Tg mice also showed significant damage and myopathy characterized by the presence of centrally nucleated myofibres, extracellular matrix expansion, and were 19-26% weaker than controls (P < 0.05). Transcriptomic analysis revealed FoxP1 as a potent transcriptional repressor of skeletal muscle gene expression, with enrichment of pathways related to skeletal muscle structure and function, growth signalling, and cell quality control. Because FoxP1 functions, at least in part, as a transcriptional repressor through its interaction with histone deacetylase proteins, we treated FoxP1iSkmTg/Tg mice with Trichostatin A, and found that this completely prevented the loss of muscle mass (p = 0.007) and fibre atrophy (P < 0.001) in the tibialis anterior. In the context of cancer, FoxP1 knockdown blocked the cancer-induced repression of myocyte enhancer factor 2 (MEF2)-target genes critical to muscle differentiation and repair, improved muscle ultrastructure, and attenuated muscle fibre atrophy by 50% (P < 0.05).CONCLUSIONS: In summary, we identify FoxP1 as a novel repressor of skeletal muscle gene expression that is increased in cancer cachexia, whose up-regulation is sufficient to induce skeletal muscle wasting and weakness, and required for the normal wasting response to cancer.

FoxP1 Represses MEF2A in Striated Muscle

Ascl2 inhibits myogenesis by antagonizing the transcriptional activity of myogenic regulatory factors

Microrna133a Targets Foxl2 and Promotes Differentiation of C2C12 into Myogenic Progenitor Cells.

Mst1-mediated phosphorylation of FoxO1 and C/EBP-β stimulates cell-protective mechanisms in cardiomyocytes

The Merg1a Channel Modulates Skeletal Muscle Murf1, but Not Mafbx, Expression

Foxo3 Knockdown Mediates Decline of Myod1 and Myog Reducing Myoblast Conversion to Myotubes

Enhanced expression of the myogenic factor Myocyte enhancer factor-2 in imaginal disc myoblasts activates a partial, but incomplete, muscle development program

Synergistic Up-Regulation of Muscle LIM Protein Expression in C2C12 and NIH3T3 Cells by Myogenin and MEF2C.

FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness

FOXO1 inhibits osteoclastogenesis partially by antagnozing MYC

Genome-wide mapping of the binding sites of myocyte enhancer factor 2A in chicken primary myoblasts

FoxO1 regulates muscle fiber-type specification and inhibits calcineurin signaling during C2C12 myoblast differentiation

Foxn1 overexpression promotes thymic epithelial progenitor cell proliferation and mTEC maintenance, but does not prevent thymic involution

Rbfox1 is required for myofibril development and maintaining fiber type-specific isoform expression in Drosophila muscles

Ebp1 Regulates Myogenic Differentiation of Myoblast Cells Via Smad2/3 Signaling Pathway

A cardiac fibrosis determinative factor, Meox1, blocks direct reprogramming of cardiac myofibroblasts to cardiomyocyte-like cells

FOXP1 acts through a negative feedback loop to suppress FOXO-induced apoptosis

E-box independent chromatin recruitment turns MYOD into a transcriptional repressor

A Novel Zinc Finger Protein Zfp637 Behaves As a Repressive Regulator in Myogenic Cellular Differentiation.

Induction of Mxi1-SR alpha by FOXO3a contributes to repression of Myc-dependent gene expression

The transcription factor EBF1 non-cell-autonomously regulates cardiac growth and differentiation